10-Q: AngioDynamics Reports Q3 Fiscal 2026 Financial Results

AngioDynamics reported a net loss of $8.1 million on $78.4 million in revenue for the third quarter of fiscal year 2026, driven by strong Med Tech segment growth.

Summary

• Net sales for the third quarter of fiscal 2026 were $78.4 million, an 8.9% increase compared to $72.0 million in the prior year period.
• Med Tech segment revenue grew 19.0% to $37.3 million, while Med Device revenue grew 1.2% to $41.1 million.
• Net loss for the quarter was $8.1 million, or $0.19 per share, compared to a net loss of $4.4 million, or $0.11 per share, in the prior year period.
• Gross margin for the quarter was 52.9%, a decrease of 110 basis points from the prior year period.
• Operating expenses for the quarter were $54.4 million, compared to $48.8 million in the prior year period.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral report; while the company is achieving strong growth in its core Med Tech segment, the continued net losses and margin compression reflect ongoing operational challenges and restructuring costs.

Positives

• Med Tech segment revenue growth of 19.0% year-over-year.
• Auryon product line sales increased by $2.5 million for the quarter.
• Thrombus management platform sales increased by $2.1 million for the quarter.
• NanoKnife sales increased by $1.3 million for the quarter.
• Total company revenue for the nine months ended February 28, 2026, increased 10.0% to $233.6 million.

Negatives

• Net loss increased to $8.1 million for the quarter from $4.4 million in the prior year period.
• Gross margin decreased 110 basis points to 52.9% for the quarter.
• Med Device gross margin decreased 320 basis points to 44.2% for the quarter.
• Operating expenses increased to $54.4 million from $48.8 million in the prior year period.
• Cash and cash equivalents decreased to $37.8 million as of February 28, 2026, from $55.9 million as of May 31, 2025.

Risks

• Ongoing product liability claims, including approximately 347 port product claims.
• Macroeconomic factors including inflation, labor shortages, and supply chain challenges.
• Potential for future product recalls or regulatory actions.
• Dependence on international distributor relationships for sales outside the U.S.
• Risks associated with the ongoing restructuring of the manufacturing footprint.

Future Outlook

The company expects to continue investing in research and development and strategic business development opportunities to drive growth. Management continues to monitor macroeconomic impacts, including supply chain and inflation, and expects to complete restructuring activities by the end of fiscal year 2026.

Management Comments

• Management focuses on company-wide and segment revenue and gross margin, operating income, earnings per share, and cash flow from operations to evaluate performance.
• Management continues to evaluate the company's liquidity position, monitor customer and supplier actions, and review near-term financial performance.

Industry Context

StockSavvy.ai notes that AngioDynamics is navigating a challenging environment characterized by healthcare provider consolidation and value-based purchasing, similar to other mid-cap medical device companies. The focus on high-growth Med Tech segments like Auryon and NanoKnife is a strategic pivot to offset slower growth in legacy Med Device products.

Comparison to Industry Standards

• The company's gross margin of 52.9% is generally consistent with mid-tier medical device manufacturers, though it faces pressure from inflationary costs and tariffs.
• The growth in the Med Tech segment (19.0%) outperforms many traditional medical device peers, reflecting successful adoption of specialized technology platforms.

Management Changes

Corporate Governance

Legal Proceedings

• Ongoing defense of approximately 347 product liability claims related to port products.
• Settlement agreement with Becton, Dickinson and Company (BD) regarding patent litigation, involving ongoing annual payments.

Related Party Transactions

• None disclosed.

Stakeholder Impact

• Shareholders: Impacted by ongoing net losses and share price volatility.
• Employees: Affected by restructuring and manufacturing footprint optimization.
• Customers: Continued reliance on company products for minimally invasive procedures.

Next Steps

• Completion of manufacturing restructuring activities by the end of fiscal year 2026.
• Execution of CEO transition following the announced retirement of James C. Clemmer.
• Continued monitoring of the $13.3 million remaining under the share repurchase program.

Key Dates

Recommendation

The company is in a transition phase with significant restructuring and leadership changes. While Med Tech growth is promising, the lack of profitability and ongoing legal risks suggest a cautious 'hold' approach until the restructuring is complete and the new CEO strategy is clarified.

Keywords

AngioDynamics, MedTech, Medical Devices, Vascular Access, Oncology, Auryon, NanoKnife, Financial Results